Evidence map›Paper›PMID 35183774›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2022

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.

Matthew P Smeltzer, Giorgio V Scagliotti, Heather A Wakelee, Tetsuya Mitsudomi, Upal Basu Roy, Russell C Clark, Renee Arndt, Clayton D Pruett, Karen L Kelly, Peter Ujhazy and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Matthew P SmeltzerDivision of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee. Electronic address: msmltzer@memphis.edu.
Giorgio V ScagliottiA.O.U. San Luigi Gonzaga Hospital, Department of Oncology, University of Torino, Orbassano, Italy.
Heather A WakeleeDivision of Oncology, Stanford University, Palo Alto, California.
Tetsuya MitsudomiDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Upal Basu RoyLUNGevity Foundation, Bethesda, Maryland.
Russell C ClarkCancer Technology Applications, LLC, San Diego, California.
Renee ArndtCancer Technology Applications, LLC, San Diego, California.
Clayton D PruettCancer Technology Applications, LLC, San Diego, California.
Karen L KellyDepartment of Medicine, Division of Hematology Oncology, University of California Davis Health, Sacramento, California.
Peter UjhazyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Melissa L JohnsonSarah Cannon Research Institute, Nashville, Tennessee; Tennessee Oncology, PLLC, Nashville, Tennessee.
Yesim EralpMaslak Acibadem Hospital, Acibadem University, Istanbul, Turkey.
Carlos H BarriosLatin American Cooperative Oncology Group (LACOG) Oncoclínicas Group, Porto Alegre, Brazil.
Fabrice BarlesiDepartment of Medical Oncology, Gustave Roussy, Villejuif, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Aix-Marseille University, Marseille, France.
Fred R HirschCenter for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Paul A BunnUniversity of Colorado School of Medicine, Aurora, Colorado.
International Association for the Study of Lung Cancer Coronavirus Disease 2019 and Clinical Trials Steering Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo evaluate the effects of the global coronavirus disease 2019 (COVID-19) pandemic on lung cancer trials, we surveyed investigators and collected aggregate enrollment data for lung cancer trials across the world before and during the pandemic.

methodsA Data Collection Survey collected aggregate monthly enrollment numbers from 294 global lung cancer trials for 2019 to 2020. A 64-question Action Survey evaluated the impact of COVID-19 on clinical trials and identified mitigation strategies implemented.

resultsClinical trial enrollment declined from 2019 to 2020 by 14% globally. Most reductions in enrollment occurred in April to June where we found significant decreases in individual site enrollment (p = 0.0309). Enrollment was not significantly different in October 2019 to December of 2019 versus 2020 (p = 0.25). The most frequent challenges identified by the Action Survey (N = 172) were fewer eligible patients (63%), decrease in protocol compliance (56%), and suspension of trials (54%). Patient-specific challenges included access to trial site (49%), ability to travel (54%), and willingness to visit the site (59%). The most frequent mitigation strategies included modified monitoring requirements (47%), telehealth visits (45%), modified required visits (25%), mail-order medications (25%), and laboratory (27%) and radiology (21%) tests at nonstudy facilities. Sites that felt the most effective mitigation strategies were telehealth visits (85%), remote patient-reported symptom collection (85%), off-site procedures (85%), and remote consenting (89%).

conclusionsThe COVID-19 pandemic created many challenges for lung cancer clinical trials conduct and enrollment. Mitigation strategies were used and, although the pandemic worsened, trial enrollment improved. A more flexible approach may improve enrollment and access to clinical trials, even beyond the pandemic.

Indexed as

COVID-19Lung NeoplasmsHumansPandemicsClinical trialsCOVID-19Lung cancerTelehealth

Identifiers

PMID35183774
PMCPMC8851565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.